53 related articles for article (PubMed ID: 23083672)
1. Practical conundrums of immune profiling in Stevens-Johnson syndrome-toxic epidermal necrolysis.
Shah S; Bishnoi A; Vinay K; Parsad D; Kumaran MS
Allergy; 2023 Dec; 78(12):3287-3288. PubMed ID: 37312644
[No Abstract] [Full Text] [Related]
2. International and multidisciplinary scientific collaborations and networks are advancing knowledge about Stevens-Johnson syndrome and toxic epidermal necrolysis.
Dodiuk-Gad RP
Br J Dermatol; 2019 Jul; 181(1):18-19. PubMed ID: 31259394
[No Abstract] [Full Text] [Related]
3. Where to place etanercept and combination treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis?
Mukherjee EM; Phillips EJ
Ann Allergy Asthma Immunol; 2022 Sep; 129(3):269-270. PubMed ID: 35988972
[No Abstract] [Full Text] [Related]
4. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.
Viscuse PV; Marques-Piubelli ML; Heberton MM; Parra ER; Shah AY; Siefker-Radtke A; Gao J; Goswami S; Ivan D; Curry JL; Campbell MT
Front Oncol; 2021; 11():621591. PubMed ID: 33747934
[TBL] [Abstract][Full Text] [Related]
6. Novel method to analyze cell kinetics for the rapid diagnosis and determination of the causative agent in allergy.
Shibaguchi H; Yasutaka Y; Futagami K
PLoS One; 2021; 16(2):e0246125. PubMed ID: 33606707
[TBL] [Abstract][Full Text] [Related]
7. An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.
Copaescu A; Gibson A; Li Y; Trubiano JA; Phillips EJ
Front Pharmacol; 2020; 11():573573. PubMed ID: 33597867
[TBL] [Abstract][Full Text] [Related]
8. The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries.
Olteanu C; Shear NH; Morita E; Chung WH; Niihara H; Matsukura S; Hashimoto R; Dodiuk-Gad RP
Drug Saf; 2019 Jun; 42(6):797-801. PubMed ID: 31037651
[No Abstract] [Full Text] [Related]
9. Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.
Bellón T
Drug Saf; 2019 Aug; 42(8):973-992. PubMed ID: 31020549
[TBL] [Abstract][Full Text] [Related]
10. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
11. Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.
Konvinse KC; Phillips EJ; White KD; Trubiano JA
Curr Opin Infect Dis; 2016 Dec; 29(6):561-576. PubMed ID: 27753687
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis.
Hoetzenecker W; Mehra T; Saulite I; Glatz M; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
F1000Res; 2016; 5():. PubMed ID: 27239294
[TBL] [Abstract][Full Text] [Related]
13. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-17 in lesions of erythema multiforme may indicate a role for T helper 17 cells.
Akkurt ZM; Uçmak D; Türkcü G; Yüksel H; Yildiz K; Arıca M
Cent Eur J Immunol; 2014; 39(3):370-6. PubMed ID: 26155150
[TBL] [Abstract][Full Text] [Related]
15. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Teraki Y; Kawabe M; Izaki S
J Allergy Clin Immunol; 2013 Mar; 131(3):907-9. PubMed ID: 23083672
[No Abstract] [Full Text] [Related]
16. Disturbed balance in three subpopulations of CD4(+)Foxp3(+) regulatory T cells in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.
Yoshioka N; Suto A; Abe R; Saito N; Murata J; Hayashi-Ujiie I; Hoshina D; Fujita Y; Shimizu H
Clin Immunol; 2013 Jul; 148(1):89-91. PubMed ID: 23665550
[No Abstract] [Full Text] [Related]
17. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.
Michael D; Grando SA
Curr Dir Autoimmun; 2008; 10():333-43. PubMed ID: 18460894
[TBL] [Abstract][Full Text] [Related]
18. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
[TBL] [Abstract][Full Text] [Related]
19. [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].
Chronopoulos A; Pleyer U; Mockenhaupt M
Klin Monbl Augenheilkd; 2012 May; 229(5):534-9. PubMed ID: 22592345
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
